Publications
Original Article
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
Clinical Trials
2021
Authors:
John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, Barbara A Goff
Journal:
Journal for ImmunoTherapy of Cancer
Volume:
9(9)
Page:
Pubmed:
Original Article
Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients
2021
Authors:
Stanton, SE, Gad E, Ramos, E, Corulli LR, Annis, J, Katayama, H, Hamash S and Disis, ML
Journal:
Nature Partner Journals Breast Cancer
Volume:
7(1)
Page:
50
Pubmed:
Original Article
Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways
Antigen Discovery & Vaccines
2021
Authors:
Cecil, D., Park, K H, Curtis, B, Corulli, L, and Disis, ML
Journal:
Journal for Immunotherapy of Cancer
Volume:
9
Page:
Pubmed:
Original Article
Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Tumor Microenvironment
2020
Authors:
Disis ML, Corulli LR, Gad EA, Koehnlein MR, Cecil DL, Senter PD, Gardai SJ, Okeley NM.
Journal:
Molecular Cancer theraputics
Volume:
19(5)
Page:
1102-1109
Pubmed:
Original Article
Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer
General Immune Research
2020
Authors:
Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C, Katayama H, Disis ML, Arun B, Hanash S.
Journal:
Journal of Natural Cancer Institute
Volume:
112(6)
Page:
607-616
Pubmed:
Original Article
Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets
Antigen Discovery & Vaccines
2019
Authors:
Stanton SE, Gad E, Corulli LR, Lu H, Disis ML.
Journal:
Vaccine
Volume:
37(27)
Page:
3552-3561
Pubmed:
Original Article
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
Clinical Trials
2019
Authors:
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.
Journal:
Jama Oncology
Volume:
5(3)
Page:
393-401
Pubmed:
Original Article
The Effect of Mouse Strain, Sex, and Carcinogen Dose on Toxicity and the Development of Lung Dysplasia and Squamous Cell Carcinomas in Mice
Animal Models
2019
Authors:
Laura Riolobos, Ekram A. Gad, Piper M. Treuting, Andrew E. Timms, Elliot A. Hershberg, Lauren R. Corulli, Erin Rodmaker and Mary L. Disis
Journal:
Cancer Prevention Research
Volume:
12(8)
Page:
507-16
Pubmed:
Original Article
A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer
General Immune Research
2019
Authors:
Katayama H, Tsou P, Kobayashi M, Capello M, Wang H, Esteva F, Disis ML, Hanash S.
Journal:
NPJ Precision Oncology
Volume:
3
Page:
10
Pubmed:
Original Article
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Clinical Trials
2018
Authors:
Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.
Journal:
Clinical Cancer Research
Volume:
24(7)
Page:
1525-1535
Pubmed: